Table 2.
Acquired FLT3 TKD mutations in patients relapsed on gilteritinib
| Subject no. | Initial dose, mg/d | Age/sex/race/weight | CR/CRh | Best overall response | Cytogenetic risk status | Timepoint | Specimen type | Blast, % | Mutation | VAF, % |
|---|---|---|---|---|---|---|---|---|---|---|
| 44 | 80 | 51 y/male/W/90.9 kg | No | CRi | Intermediate: normal | Screening | Bone marrow | 81 | ITD | 63.41 |
| EOT (relapse) | Blood | 30 | ITD | 54.91 | ||||||
| p.N609T | 0.86 | |||||||||
| 51 | 40 | 73 y/male/W/88.6 kg | No | NR | Unfavorable: complex | Screening | Bone marrow | 88 | ITD | 48.44 |
| p.D835Y | 2.98 | |||||||||
| EOT (relapse) | Bone marrow | 68 | ITD | 53.12 | ||||||
| p.F691L | 7.31 | |||||||||
| p.F691L | 10.7 | |||||||||
| 124 | 80 | 67 y/male/W/91.6 kg | No | CRi | Intermediate: normal | Screening | Bone marrow | 2 | ITD | 26.77 |
| p.D835Y | 3.33 | |||||||||
| EOT (relapse) | Blood | 4 | ITD | 29.6 | ||||||
| p.F691L | 5.39 | |||||||||
| p.D835Y | 7.85 | |||||||||
| 142 | 120 | 84 y/male/W/83.9 kg | Yes | CRi | Intermediate: +8 | Screening | Bone marrow | 56 | ITD | 65.3 |
| p.D835H | 18.51 | |||||||||
| Cycle 8, day 1 (relapse) | Blood | 14 | ITD | 40.6 | ||||||
| p.F691L | 2.16 | |||||||||
| p.F691L | 4.9 | |||||||||
| 146 | 120 | 30 y/female/W/124.1 kg | Yes | CRi | Favorable: inv(16) | Screening | Bone marrow | 58 | ITD | 48.71 |
| EOT (relapse) | Blood | 22 | ITD | 28.14 | ||||||
| p.F691L | 4.09 |